| Dr Nikunjkumar Trambaklal Modi, MD | |
|
600 E Palmetto St, Florence, SC 29506-2851 | |
| (843) 667-9414 | |
| (843) 667-1362 |
| Full Name | Dr Nikunjkumar Trambaklal Modi |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 20 Years |
| Location | 600 E Palmetto St, Florence, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003131343 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 37807 (South Carolina) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mcleod Physician Associates Ii | 8224031307 | 520 |
| South Carolina Dept Of Mental Health Accounting Office | 9032021175 | 166 |
News Archive
Shire plc, the global specialty biopharmaceutical company, today presented positive top line results of the first European phase III study of once-daily lisdexamfetamine dimesylate (LDX) in children and adolescents aged 6 to 17 years with Attention-Deficit/Hyperactivity Disorder.
Despite treatment with imatinib, a successful drug that targets chronic myeloid leukemia (CML), a deadly type of cancer, some patients may continue to be at risk for relapse because a tiny pool of stem cells is resistant to treatment and may even accumulate additional genetic aberrations, eventually leading to disease progression and relapse. These leukemia stem cells are full of genetic errors, loaded with potentially lethal breaks in DNA, and are in a state of constant self-repair.
Smith & Nephew's Endoscopy Division today announced the launch of the DYONICS™ RF System, which incorporates a compact generator with a family of probes for aggressively removing defects and smoothing soft tissue during arthroscopic surgery.
A team of scientists from China and the USA has recently described the antiviral efficacy of a monoclonal antibody candidate targeting the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Importantly, they have observed that emerging spike mutations could not affect the potency of this antibody. The study is currently available on the bioRxiv* preprint server.
› Verified 6 days ago
| Entity Name | South Carolina Dept Of Mental Health Accounting Office |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295332690 PECOS PAC ID: 9032021175 Enrollment ID: O20031107000041 |
News Archive
Shire plc, the global specialty biopharmaceutical company, today presented positive top line results of the first European phase III study of once-daily lisdexamfetamine dimesylate (LDX) in children and adolescents aged 6 to 17 years with Attention-Deficit/Hyperactivity Disorder.
Despite treatment with imatinib, a successful drug that targets chronic myeloid leukemia (CML), a deadly type of cancer, some patients may continue to be at risk for relapse because a tiny pool of stem cells is resistant to treatment and may even accumulate additional genetic aberrations, eventually leading to disease progression and relapse. These leukemia stem cells are full of genetic errors, loaded with potentially lethal breaks in DNA, and are in a state of constant self-repair.
Smith & Nephew's Endoscopy Division today announced the launch of the DYONICS™ RF System, which incorporates a compact generator with a family of probes for aggressively removing defects and smoothing soft tissue during arthroscopic surgery.
A team of scientists from China and the USA has recently described the antiviral efficacy of a monoclonal antibody candidate targeting the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Importantly, they have observed that emerging spike mutations could not affect the potency of this antibody. The study is currently available on the bioRxiv* preprint server.
› Verified 6 days ago
| Entity Name | Mcleod Regional Medical Center Of The Pee Dee, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154371433 PECOS PAC ID: 7416851852 Enrollment ID: O20031126000251 |
News Archive
Shire plc, the global specialty biopharmaceutical company, today presented positive top line results of the first European phase III study of once-daily lisdexamfetamine dimesylate (LDX) in children and adolescents aged 6 to 17 years with Attention-Deficit/Hyperactivity Disorder.
Despite treatment with imatinib, a successful drug that targets chronic myeloid leukemia (CML), a deadly type of cancer, some patients may continue to be at risk for relapse because a tiny pool of stem cells is resistant to treatment and may even accumulate additional genetic aberrations, eventually leading to disease progression and relapse. These leukemia stem cells are full of genetic errors, loaded with potentially lethal breaks in DNA, and are in a state of constant self-repair.
Smith & Nephew's Endoscopy Division today announced the launch of the DYONICS™ RF System, which incorporates a compact generator with a family of probes for aggressively removing defects and smoothing soft tissue during arthroscopic surgery.
A team of scientists from China and the USA has recently described the antiviral efficacy of a monoclonal antibody candidate targeting the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Importantly, they have observed that emerging spike mutations could not affect the potency of this antibody. The study is currently available on the bioRxiv* preprint server.
› Verified 6 days ago
| Entity Name | Mcleod Physician Associates Ii |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801990494 PECOS PAC ID: 8224031307 Enrollment ID: O20060926000568 |
News Archive
Shire plc, the global specialty biopharmaceutical company, today presented positive top line results of the first European phase III study of once-daily lisdexamfetamine dimesylate (LDX) in children and adolescents aged 6 to 17 years with Attention-Deficit/Hyperactivity Disorder.
Despite treatment with imatinib, a successful drug that targets chronic myeloid leukemia (CML), a deadly type of cancer, some patients may continue to be at risk for relapse because a tiny pool of stem cells is resistant to treatment and may even accumulate additional genetic aberrations, eventually leading to disease progression and relapse. These leukemia stem cells are full of genetic errors, loaded with potentially lethal breaks in DNA, and are in a state of constant self-repair.
Smith & Nephew's Endoscopy Division today announced the launch of the DYONICS™ RF System, which incorporates a compact generator with a family of probes for aggressively removing defects and smoothing soft tissue during arthroscopic surgery.
A team of scientists from China and the USA has recently described the antiviral efficacy of a monoclonal antibody candidate targeting the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Importantly, they have observed that emerging spike mutations could not affect the potency of this antibody. The study is currently available on the bioRxiv* preprint server.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Nikunjkumar Trambaklal Modi, MD 360 N Irby St, Florence, SC 29501-2808 Ph: (843) 667-9414 | Dr Nikunjkumar Trambaklal Modi, MD 600 E Palmetto St, Florence, SC 29506-2851 Ph: (843) 667-9414 |
News Archive
Shire plc, the global specialty biopharmaceutical company, today presented positive top line results of the first European phase III study of once-daily lisdexamfetamine dimesylate (LDX) in children and adolescents aged 6 to 17 years with Attention-Deficit/Hyperactivity Disorder.
Despite treatment with imatinib, a successful drug that targets chronic myeloid leukemia (CML), a deadly type of cancer, some patients may continue to be at risk for relapse because a tiny pool of stem cells is resistant to treatment and may even accumulate additional genetic aberrations, eventually leading to disease progression and relapse. These leukemia stem cells are full of genetic errors, loaded with potentially lethal breaks in DNA, and are in a state of constant self-repair.
Smith & Nephew's Endoscopy Division today announced the launch of the DYONICS™ RF System, which incorporates a compact generator with a family of probes for aggressively removing defects and smoothing soft tissue during arthroscopic surgery.
A team of scientists from China and the USA has recently described the antiviral efficacy of a monoclonal antibody candidate targeting the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Importantly, they have observed that emerging spike mutations could not affect the potency of this antibody. The study is currently available on the bioRxiv* preprint server.
› Verified 6 days ago
Dr. Roland L Skinner Iii, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 800 E Cheves St, Suite 380, Florence, SC 29506 Phone: 843-665-4104 | |
Dr. Paul Phillip Lowe, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 656 S Coit St, Florence, SC 29501 Phone: 843-413-5009 Fax: 843-667-0881 | |
Robert Joseph Healy Jr., MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 805 Pamplico Hwy, Suite A130, Florence, SC 29505 Phone: 843-664-9200 Fax: 843-664-9202 | |
Barbara L Sarb, DO Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1204 E Cheves St, Florence, SC 29506 Phone: 843-673-0122 Fax: 843-661-6400 | |
Elijah D Owens, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1594 Freedom Blvd, Suite 305, Florence, SC 29505 Phone: 843-669-0927 Fax: 843-665-9323 | |
Dr. Dong Ha Chung, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 402 Burris Rd, Florence, SC 29501 Phone: 843-992-3766 |